Novartis gets CDSCO panel go ahead for Asciminib Phase 3 trial
Advertisement
In a significant development, major drug-maker Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of Asciminib, a Tyrosine Kinase Inhibitor (TKI) for the treatment of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.
This came in wake of the Phase III clinical trial protocol presented by Novartis at the recent SEC meeting for Oncology and Haematology.
For more details, check out the full story on the link below:
Novartis Gets CDSCO Panel Nod To Conduct Phase 3 Study Of Anti-Cancer Drug Asciminib
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.